Plasma-derived Alpha-1 Antitrypsin: Phase II started

Omni Bio said investigators at the University of Michigan Cancer Center began an open-label, U.S. Phase II trial to evaluate twice-weekly, 60 mg/kg AAT for 4 weeks in about 40 patients. Omni Bio said...